Wechselwirkungen · Febuxostat Viatris (previously Febuxostat Mylan)
Febuxostat Viatris 80 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-138243 · Präparat HOS-098172
On the basis of the mechanism of action of febuxostat on XO inhibition concomitant use is not recommended. Inhibition of XO by febuxostat may cause increased plasma concentrations of these drugs leading to myelotoxicity. In case of concomitant administration with febuxostat, the dose of mercaptopurine/azathioprine should be reduced to 20% or less of the previously prescribed dose (see sections 4.4 and 5.3). The adequacy of the proposed dose adjustment, which was based on a modelling and simulation analysis from preclinical data in rats, was confirmed by the results of a clinical drug-drug interaction study in healthy volunteers, receiving azathioprine 100 mg alone and a reduced dose of azathioprine (25 mg) in combination with febuxostat (40 or 120 mg).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): mercaptopurine (HOS-085568) azathioprine (HOS-089001)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-19T12:27:00Z · SHA-256 ac16ec383402e83b4c7edeaa05de017d6cff004a74883ae519779585c1442c60 · Passage db93175b206e090db407cf20c72489b30cded866ca2d0c253710cbbce9bb5785 · Zeichen 29–791 im Abschnitt